ReviewDiabetes & metabolism2019

Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.

V R Aroda et al.PubMed ↗Publisher ↗

No numbers read from the abstract.